The investment will support accelerated clinical development of TargED’s lead program, TGD001, a firstin-class, targeted thrombolytic designed to treat a broad range of thrombotic events by degrading both von Willebrand factor (VWF) and fibrin. The financing enables expansion of two Phase 1/2 clinical studies across Europe and the U.S. with first data expected later this year. In December 2025, the company reported positive Phase 1 first-in-human results for TGD001, demonstrating a favorable safety profile with no spontaneous bleeding events and exhibiting potent thrombolytic activity. Data were first presented in an oral session at the American Society of Hematology (ASH) Annual Meeting in December 2025 and updates presented in May 2026 at the European Stroke Organization Conference (ESOC).

“We are delighted to be expanding our syndicate with prestigious investors who share our conviction for TGD001, and are grateful for the continued support from all our existing investors,” said Kristof Vercruysse, Chief Executive Officer of TargED Biopharmaceuticals. “The momentum behind TGD001 continues to build, we are now well positioned to expand clinical development towards proof of concept in at least two indications. We believe TGD001 has the potential to fundamentally reshape the treatment of thrombosis, offering a novel approach to universally dissolving life-threatening clots across multiple indications.”

“We have seen TargED mature into a clinical stage biotech leading development in indications that sadly have seen little to no innovation in decades. Today, TargED stands at the forefront of innovation in targeted thrombolysis and we are thrilled to be joining as a new investor,” said Rémi Droller, Managing Partner at Kurma Partners. “We are looking forward to working with the team to transform the treatment of thrombotic diseases”.

“Europe’s ability to lead in healthcare innovation depends on turning scientific breakthroughs into solutions that can address major unmet needs. TargED exemplifies the ambition we want to support: a European deep tech company translating cutting-edge biotechnology into a new approach for treating life-threatening thrombotic diseases. We’re proud to support the company as it advances towards clinical milestones and brings its technology closer to patients.” – Hermann Hauser, Board Member of the EIC Fund. Investor Syndicate TargED’s investor base includes Andera Partners, BioGeneration Ventures, Curie Capital, European Innovation Council (EIC) Fund, FIRST, Fund+, Hadean Ventures, Inkef, Kurma Partners (Eurazeo Group), Sunstone Life Science Ventures, and Utrecht Health Seed Fund. 

About TargED Biopharmaceuticals

TargED Biopharmaceuticals B.V. is a clinical-stage biotechnology company pioneering targeted enzyme delivery for improved treatment of thrombotic diseases. Founded in 2020 as a spin-off from the University Medical Center Utrecht, the company has raised more than €80 million to advance its pipeline and was awarded a prestigious blended finance grant from the European Innovation Council (EIC) Accelerator Program in 2025. For more information, please visit www.targedbio.com.

About TGD001

TGD001 is a first-in-class, targeted thrombolytic designed to treat a broad range of thrombotic events. As an antibody-enzyme fusion protein, it binds to von Willebrand factor (VWF) and promotes sitespecific clot breakdown through the enzyme urokinase. Unlike currently approved therapies, TGD001 leverages the ubiquitous presence of VWF in all clots, enabling broad clot lysis by degrading both VWF and fibrin. TGD001 demonstrated compelling Phase 1 results and is in development for the treatment of acute ischemic stroke (AIS) and thrombotic microangiopathies (TMAs), including immune thrombotic thrombocytopenic purpura (iTTP).